restricting the use of Tasmar (tolcapone) due to reports of serious hepatotoxicity

The FDA recommends restricting the use of Tasmar (tolcapone) due to reports of serious hepatotoxicity...including three deaths.

Tasmar came out earlier this year. It's used to prolong the effect of levodopa in patients with advanced Parkinson's.

Now the FDA recommends limiting Tasmar to patients who can't take or don't respond to other Parkinson's drugs.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote